Clinical Trials

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Number: NCT02266745
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Phosplatin Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Gallium-68 Citrate PET Used in Prostate Cancer

Number: NCT02391025
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Rahul Aggarwal|United States Department of Defense|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Number: NCT02452008
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Eli Lilly and Company
Sponsor Trial Information
Trial Location(s) and Contact(s)
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can

Number: NCT02484404
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer

Number: NCT02516670
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression

Number: NCT02555189
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University|Novartis|Prostate Cancer Clinical Trials Consortium|Thomas Jefferson University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

Number: NCT02566772
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Taiho Oncology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Number: NCT02635672
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Vincerx Pharma, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Number: NCT02649790
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Karyopharm Therapeutics Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Number: NCT02744287
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Bellicum Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Number: NCT02769962
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer

Number: NCT02809690
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Southern California|National Cancer Institute (NCI)|National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041

Number: NCT02826382
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Five Eleven Pharma, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Number: NCT02861573
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Number: NCT02933255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

Number: NCT02935205
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Mamta Parikh|National Cancer Institute (NCI)|University of California, Davis
Sponsor Trial Information
Trial Location(s) and Contact(s)
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Number: NCT03012321
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Northwestern University|AstraZeneca|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Number: NCT03016741
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 4
Sponsor(s): Northwestern University
Sponsor Trial Information
Trial Location(s) and Contact(s)
INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers

Number: NCT03071328
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Duke University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer

Number: NCT03073395
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Five Eleven Pharma, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer

Number: NCT03089203
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Pennsylvania
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideâ„¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

Number: NCT03129139
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Minneamrita Therapeutics LLC|Translational Drug Development
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Number: NCT03170960
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Number: NCT03207867
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Novartis Pharmaceuticals|Novartis
Sponsor Trial Information
Trial Location(s) and Contact(s)
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

Number: NCT03232164
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): University of Wisconsin, Madison
Sponsor Trial Information
Trial Location(s) and Contact(s)
Cisplatin in Castration Resistant Prostate Cancer

Number: NCT03275857
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): University of Rochester|Roswell Park Cancer Institute
Sponsor Trial Information
Trial Location(s) and Contact(s)
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

Number: NCT03317392
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Number: NCT03344211
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Southern California|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Number: NCT03361735
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): City of Hope Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Number: NCT03388619
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer

Number: NCT03392181
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Northwestern University|Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Number: NCT03406858
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Number: NCT03414034
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Cardiff Oncology
Sponsor Trial Information
Trial Location(s) and Contact(s)
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

Number: NCT03436485
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Orion Corporation, Orion Pharma
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

Number: NCT03437941
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Corcept Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Number: NCT03454451
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Corvus Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

Number: NCT03456843
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Yale University|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Number: NCT03460977
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

Number: NCT03493945
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

Number: NCT03507608
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Number: NCT03517488
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Xencor, Inc.|ICON plc
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Number: NCT03549000
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Novartis Pharmaceuticals|Novartis
Sponsor Trial Information
Trial Location(s) and Contact(s)
Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma

Number: NCT03556228
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): VM Oncology, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study to Evaluate CCS1477 in Advanced Tumours

Number: NCT03568656
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): CellCentric Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

Number: NCT03569280
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Kangpu Biopharmaceuticals, Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Number: NCT03574571
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Memorial Sloan Kettering Cancer Center|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Number: NCT03575819
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Fortis Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of HPN424 in Patients With Advanced Prostate Cancer

Number: NCT03577028
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Harpoon Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

Number: NCT03585114
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Emerson Lim|Columbia University
Sponsor Trial Information
Trial Location(s) and Contact(s)
This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer

Number: NCT03592264
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): OBI Pharma, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy

Number: NCT03619655
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT)

Number: NCT03663218
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Weill Medical College of Cornell University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Number: NCT03674814
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Chicago|Corcept Therapeutics|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

Number: NCT03706365
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2|Phase 3
Sponsor(s): Eli Lilly and Company
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

Number: NCT03724747
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Number: NCT03725761
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Wisconsin, Madison|National Cancer Institute (NCI)|Gilead Sciences
Sponsor Trial Information
Trial Location(s) and Contact(s)
MGC018 With or Without MGA012 in Advanced Solid Tumors

Number: NCT03729596
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): MacroGenics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

Number: NCT03737370
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Tufts Medical Center|Bayer|Lahey Clinic|Henry Ford Hospital|Ohio State University Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Number: NCT03751436
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Roswell Park Cancer Institute|AbbVie
Sponsor Trial Information
Trial Location(s) and Contact(s)
MGD019 DART® Protein in Unresectable/Metastatic Cancer

Number: NCT03761017
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): MacroGenics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma

Number: NCT03775525
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Genzada Pharmaceuticals USA, Inc.|Translational Drug Development
Sponsor Trial Information
Trial Location(s) and Contact(s)
SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors

Number: NCT03784677
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects with MCRPC

Number: NCT03792841
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Amgen
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of ASP1951 in Subjects With Advanced Solid Tumors

Number: NCT03799003
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Astellas Pharma Global Development, Inc.|Merck Sharp & Dohme Corp.|Astellas Pharma Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Number: NCT03805594
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of California, San Francisco|Prostate Cancer Foundation|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

Number: NCT03822871
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Cancer Targeted Technology|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer

Number: NCT03824275
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2|Phase 3
Sponsor(s): Columbia University
Sponsor Trial Information
Trial Location(s) and Contact(s)
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy

Number: NCT03824652
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Stephen Freedland|California Walnut Commission|Cedars-Sinai Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery

Number: NCT03824808
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 4
Sponsor(s): University of Missouri-Columbia
Sponsor Trial Information
Trial Location(s) and Contact(s)
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Number: NCT03829436
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Tempest Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Number: NCT03834493
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

Number: NCT03835533
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Parker Institute for Cancer Immunotherapy|Bristol-Myers Squibb|Celldex Therapeutics|Cancer Research Institute, New York City|Inovio Pharmaceuticals|Oncovir, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Number: NCT03837353
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): NYU Langone Health|Leap Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Number: NCT03845166
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Number: NCT03849469
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Xencor, Inc.|ICON Clinical Research
Sponsor Trial Information
Trial Location(s) and Contact(s)
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Number: NCT03850795
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Hinova Pharmaceuticals USA, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Number: NCT03866382
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

Number: NCT03873805
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): City of Hope Medical Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Number: NCT03878524
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): OHSU Knight Cancer Institute|Oregon Health and Science University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

Number: NCT03888612
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Arvinas Androgen Receptor, Inc.|Arvinas Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer

Number: NCT03899467
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Suzhou Kintor Pharmaceutical Inc,
Sponsor Trial Information
Trial Location(s) and Contact(s)
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Number: NCT03934840
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Masonic Cancer Center, University of Minnesota
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone

Number: NCT03939689
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy

Number: NCT03949517
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Andrei Iagaru|General Electric|Stanford University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

Number: NCT03972657
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Regeneron Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients

Number: NCT03987217
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): University of Utah|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Number: NCT04032704
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Seagen Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

Number: NCT04038502
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): VA Office of Research and Development
Sponsor Trial Information
Trial Location(s) and Contact(s)
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Number: NCT04060394
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Laekna Limited
Sponsor Trial Information
Trial Location(s) and Contact(s)
Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer

Number: NCT04067960
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Mayo Clinic|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

Number: NCT04068896
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): NGM Biopharmaceuticals, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

Number: NCT04077021
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Calibr, a division of Scripps Research
Sponsor Trial Information
Trial Location(s) and Contact(s)
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Number: NCT04090528
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Wisconsin, Madison|Merck Sharp & Dohme Corp.|Madison Vaccines, Inc|Prostate Cancer Foundation
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

Number: NCT04100018
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Number: NCT04104776
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Constellation Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

Number: NCT04104893
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): VA Office of Research and Development|Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer

Number: NCT04109729
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): University of Utah
Sponsor Trial Information
Trial Location(s) and Contact(s)
Safety and Targeting of Anti-hk2 Antibody in mCRPC

Number: NCT04116164
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Tomopath Inc.|Invicro|Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Number: NCT04116775
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Julie Graff, MD|Merck Sharp & Dohme Corp.|Prostate Cancer Foundation|Johns Hopkins University|Oregon Health and Science University|Portland VA Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Number: NCT04140526
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): OncoC4, Inc.|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)

Number: NCT04157088
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

Number: NCT04158245
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Tulane University|Blue Earth Diagnostics
Sponsor Trial Information
Trial Location(s) and Contact(s)
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Number: NCT04159896
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
CELLO-1, Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy

Number: NCT04179864
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Epizyme, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors

Number: NCT04182516
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Nerviano Medical Sciences
Sponsor Trial Information
Trial Location(s) and Contact(s)
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Number: NCT04207255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Medical University of South Carolina|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer

Number: NCT04220983
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Weill Medical College of Cornell University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Number: NCT04221542
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Amgen
Sponsor Trial Information
Trial Location(s) and Contact(s)
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Number: NCT04246671
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Bavarian Nordic
Sponsor Trial Information
Trial Location(s) and Contact(s)
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Number: NCT04249947
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Poseida Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Number: NCT04253262
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Brown University|Rhode Island Hospital|The Miriam Hospital|Bayer|Clovis Oncology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Number: NCT04279561
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Jonsson Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
PK and Dose Escalation and Expansion Study of DST-2970

Number: NCT04291664
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): DisperSol Technologies, LLC|Translational Drug Development
Sponsor Trial Information
Trial Location(s) and Contact(s)
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Number: NCT04335682
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Alliance Foundation Trials, LLC.|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

Number: NCT04337580
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Wake Forest University Health Sciences|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)

Number: NCT04349501
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, San Diego
Sponsor Trial Information
Trial Location(s) and Contact(s)
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Number: NCT04363164
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|United States Department of Defense
Sponsor Trial Information
Trial Location(s) and Contact(s)
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Number: NCT04381832
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Arcus Biosciences, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Number: NCT04382898
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): BioNTech SE
Sponsor Trial Information
Trial Location(s) and Contact(s)
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Number: NCT04388852
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

Number: NCT04397276
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

Number: NCT04421222
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): ESSA Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Number: NCT04428788
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Celgene
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Number: NCT04446117
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Exelixis|Roche-Genentech|Takeda
Sponsor Trial Information
Trial Location(s) and Contact(s)
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation

Number: NCT04457232
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Jonsson Comprehensive Cancer Center|Prostate Cancer Foundation
Sponsor Trial Information
Trial Location(s) and Contact(s)
Impact of Acetazolamide in Reducing Referred Postoperative Pain

Number: NCT04470843
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Medical College of Wisconsin
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy

Number: NCT04471727
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Harpoon Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Number: NCT04471974
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rahul Aggarwal|Zenith Epigenetics|Merck Sharp & Dohme Corp.|U.S. Army Medical Research and Development Command|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Number: NCT04485013
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Tizona Therapeutics, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)

Number: NCT04486755
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Maryland, Baltimore
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic

Number: NCT04497844
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Number: NCT04503265
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): AtlasMedx, Incorporated
Sponsor Trial Information
Trial Location(s) and Contact(s)
Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

Number: NCT04506567
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Weill Medical College of Cornell University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Number: NCT04514484
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Number: NCT04521686
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Eli Lilly and Company|Loxo Oncology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer

Number: NCT04528199
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|FutureChem
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

Number: NCT04541225
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Nuvation Bio Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Number: NCT04556617
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Plexxikon
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Number: NCT04564027
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): AstraZeneca
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of FT-7051 in Men With MCRPC

Number: NCT04575766
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Forma Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Re-treatment 225Ac-J591 for mCRPC

Number: NCT04576871
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Weill Medical College of Cornell University
Sponsor Trial Information
Trial Location(s) and Contact(s)
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Number: NCT04580485
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Incyte Corporation
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Number: NCT04586335
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Haihe Biopharma Co., Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Number: NCT04592237
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|Janssen Pharmaceutica
Sponsor Trial Information
Trial Location(s) and Contact(s)
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

Number: NCT04597359
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Number: NCT04606446
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones

Number: NCT04616547
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of CC-90011 and Comparators in Participants With Prostate Cancer

Number: NCT04628988
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Celgene
Sponsor Trial Information
Trial Location(s) and Contact(s)
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Number: NCT04631601
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Amgen
Sponsor Trial Information
Trial Location(s) and Contact(s)
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Number: NCT04631744
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Weill Medical College of Cornell University|Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s)
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

Number: NCT04633252
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

Number: NCT04634344
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Dizal Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Number: NCT04644770
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

Number: NCT04647526
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): POINT Biopharma
Sponsor Trial Information
Trial Location(s) and Contact(s)
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Number: NCT04660929
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Carisma Therapeutics Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
ARX517 in Subjects With Advanced Solid Tumor

Number: NCT04662580
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Ambrx, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Number: NCT04666129
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Myovant Sciences GmbH
Sponsor Trial Information
Trial Location(s) and Contact(s)
177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

Number: NCT04689828
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Novartis Pharmaceuticals|Novartis
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resist

Number: NCT04691804
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Jiangsu HengRui Medicine Co., Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

Number: NCT04698564
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Maryland, Baltimore
Sponsor Trial Information
Trial Location(s) and Contact(s)
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Number: NCT04703920
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Michigan Rogel Cancer Center|Pfizer|Acrotech Biopharma LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Number: NCT04709276
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Andrew J. Armstrong, MD|Bristol-Myers Squibb|Duke University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer

Number: NCT04725903
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s): Emory University|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Number: NCT04726332
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s)
Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

Number: NCT04729114
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Propella Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer

Number: NCT04737109
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): David VanderWeele|Big Ten Cancer Research Consortium
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of TNB-585 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

Number: NCT04740034
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Amgen
Sponsor Trial Information
Trial Location(s) and Contact(s)
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

Number: NCT04743934
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Andrew McDonald|University of Alabama at Birmingham
Sponsor Trial Information
Trial Location(s) and Contact(s)
Abemaciclib With or Without Atezolizumab for mCRPC

Number: NCT04751929
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Dana-Farber Cancer Institute|Eli Lilly and Company|Genentech, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Number: NCT04754191
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Utah|Astellas Pharma Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Number: NCT04754425
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors

Number: NCT04768868
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Impact Therapeutics, Inc.|Covance
Sponsor Trial Information
Trial Location(s) and Contact(s)
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer

Number: NCT04777071
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington
Sponsor Trial Information
Trial Location(s) and Contact(s)
Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Number: NCT04781374
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Dana-Farber Cancer Institute|Puma Biotechnology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Number: NCT04821622
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Pfizer|Astellas Pharma Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer

Number: NCT04842890
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): The New York Proton Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Number: NCT04844749
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Veru Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Number: NCT04846478
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Dana-Farber Cancer Institute|Epizyme, Inc.|Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

Number: NCT04848337
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Ulka Vaishampayan|Merck Sharp & Dohme Corp.|University of Michigan|Hoosier Cancer Research Network
Sponsor Trial Information
Trial Location(s) and Contact(s)
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

Number: NCT04857502
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Jonsson Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions

Number: NCT04867603
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Norbert Avril, M.D.|Case Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Number: NCT04868604
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Clarity Pharmaceuticals Ltd
Sponsor Trial Information
Trial Location(s) and Contact(s)
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

Number: NCT04879940
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute
Sponsor Trial Information
Trial Location(s) and Contact(s)
225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC

Number: NCT04886986
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Weill Medical College of Cornell University|POINT Biopharma
Sponsor Trial Information
Trial Location(s) and Contact(s)
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

Number: NCT04887506
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Tavanta Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Number: NCT04890613
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Senhwa Biosciences, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Number: NCT04898634
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Number: NCT04926181
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rahul Aggarwal|Janssen Scientific Affairs, LLC|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer

Number: NCT04927663
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Michael Evans|U.S. Army Medical Research Acquisition Activity|National Institute of Mental Health (NIMH)|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Number: NCT04931823
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Conjupro Biotherapeutics, Inc.|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC

Number: NCT04946370
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Weill Medical College of Cornell University|United States Department of Defense|Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Number: NCT04957290
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Noxopharm Limited
Sponsor Trial Information
Trial Location(s) and Contact(s)
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion

Number: NCT04976257
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Ryan Kohlbrenner, MD|Radiological Society of North America|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer

Number: NCT04984343
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Weill Medical College of Cornell University|Viewray Inc.|Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Number: NCT04986423
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Zenith Epigenetics|Astellas Pharma Inc|Newsoara Biopharma Co., Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Prostate Cancer Registry of Outcomes and Germline Mutations (PROMISE)

Number: NCT04995198
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s): Prostate Cancer Clinical Trials Consortium|Memorial Sloan Kettering Cancer Center|Fred Hutchinson Cancer Research Center|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Advancing Cancer Treatment, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Number: NCT05005728
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Xencor, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

Number: NCT05010200
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Ashutosh Kumar Tewari|Icahn School of Medicine at Mount Sinai
Sponsor Trial Information
Trial Location(s) and Contact(s)
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Number: NCT05011188
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Rahul Aggarwal|Fortis Therapeutics, Inc.|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

Number: NCT05022849
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Number: NCT05037500
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Roswell Park Cancer Institute|National Comprehensive Cancer Network
Sponsor Trial Information
Trial Location(s) and Contact(s)
Differences in Immunological Effects of Vitamin D Replacement Among African American Prostate Cancer Patients With Localized Versus Metastatic Disease

Number: NCT05045066
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Mayo Clinic|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
KZR-261 in Subjects With Advanced Solid Malignancies

Number: NCT05047536
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Kezar Life Sciences, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Number: NCT05050084
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer

Number: NCT05053152
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring

Number: NCT05054296
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Clinical Trial to Evaluate ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer

Number: NCT05067140
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Arvinas Androgen Receptor, Inc.|Arvinas Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With mCRPC

Number: NCT05075577
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): ESSA Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Number: NCT05084859
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Biosplice Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Adult Male Patients With Metastatic Castration-Resistant Prostate Cancer

Number: NCT05125016
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Regeneron Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of PRT2527 in Patients With Advanced Solid Tumors

Number: NCT05159518
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Prelude Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

Number: NCT05160597
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Jonsson Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Number: NCT05168618
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Utah|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Number: NCT05169684
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer

Number: NCT05169970
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Memorial Sloan Kettering Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors

Number: NCT05176483
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s)
Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Number: NCT05177042
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Arvinas Androgen Receptor, Inc.|Arvinas Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Number: NCT05177770
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Surface Oncology|Arcus Biosciences, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Number: NCT05204927
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Curium US LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Number: NCT05215574
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): NGM Biopharmaceuticals, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
Targeted Alpha Therapy With 225Actinium-PSMA-I&T of Castration-resISTant Prostate Cancer (TATCIST).

Number: NCT05219500
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Excel Diagnostics and Nuclear Oncology Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
PET Imaging Study of 89Zr-DFO-YS5

Number: NCT05245006
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Robert Flavell, MD, PhD|United States Department of Defense|Fortis Therapeutics, Inc.|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

Number: NCT05249127
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Clarity Pharmaceuticals Ltd
Sponsor Trial Information
Trial Location(s) and Contact(s)
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Number: NCT05252390
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Nuvation Bio Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

Number: NCT05268666
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Jubilant Therapeutics Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Number: NCT05293496
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): MacroGenics
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Number: NCT05295927
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)

Total: 227 Clinical Trials















PHEN,Inc. © 2022 All rights reserved